Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Duchenne Muscular Dystrophy: Pipeline And Partnering Snapshot

Executive Summary

A full pipeline of symptomatic and disease-modifying treatments for Duchenne will transform a long dormant orphan market into a hotly contested commercial prize. But some issues, foremost the scarcity of trial patients, threaten to stall progress in the field.

You may also be interested in...



Nascent Sarcopenia Pipeline’s First Target Is Myostatin

Biologics affecting myostatin signaling are at the forefront of the R&D pipeline for sarcopenia, with leading candidates in Phase II from Sanofi/Regeneron, Lilly and Novartis.

DMD Development Landscape Shifts After Prosensa Failure; Sarepta Continues Strong

The race to get a Duchenne muscular dystrophy drug to market has been closely watched by investors; new developments in drugs by Prosensa and Sarepta have created an unexpected change in the landscape of treatment development.

Shkreli’s Retrophin Gets Another Injection Of Capital; Talks Up Clinical Plans

The biotech, founded in late 2011 by venture capitalist Martin Shkreli, has yet to make any significant clinical moves with the compounds in its pipeline, but signs show that could change before year-end.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS054809

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel